N/A
N=1,420
Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix)
Coronary Disease
Bottom Line
View on ClinicalTrials.gov: NCT02073331 ↗Enrolled (actual)
1,420
Serious AEs
0.0%
Results posted
Oct 2019
Primary outcome: Primary: Proportion of Subjects With Device Related Adverse Events. — 0 Proportion of subjects
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Elutia Inc.
- Primary completion
- Dec 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Subjects With Device Related Adverse Events. |
— | — |
Summary
The objective of the study is to actively gather additional information on the use of CorMatrix ECM for pericardial reconstruction.
Eligibility Criteria
Inclusion Criteria
- Subjects who have received CorMatrix ECM for pericardial reconstruction
- Sign an Informed Consent
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT02073331). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.